Welcome back to MedfyleToday, your source of daily highlights from the American Diabetes Association's 83rd Scientific Sessions®.

Today, we had the opportunity to speak with Matthias Tschöp, MD, the recipient of the 2023 Banting Medal for Scientific Achievement. In our interview, Dr. Tschöp discusses dual incretin agonists, triagonists, and the future of antiobesity agents. Additionally, watch the interview on the results of the OASIS 1 and PIONEER PLUS Trials on oral semaglutide for type 2 diabetes. To help us understand the impact of these trials, we interviewed Sean Wharton, MD, PharmD, and Vanita Aroda, MD. Do the results open the doors for the use of oral semaglutide at higher doses? Can an oral formulation help more patients meet their treatment goals? Listen to the experts express their opinions.

Today’s picks include the 2023 Banting Medal for Scientific Achievement lecture, “Overcoming Obesity—The Discovery of Multi Receptor Drugs” and the President, Medicine & Science Address “My Journey in Diabetes Care, Research, and Complications” presented by Rodica Busui, MD, PhD, from the University of Michigan. Be sure to watch both presentations: you won’t be disappointed. Lastly, an interesting presentation by Alka Kanaya, MD, who received the Kelly West Award for Outstanding Achievement in Epidemiology. Her presentation was titled “Diabetes in South Asians—Uncovering Novel Risk Factors with Longitudinal Epidemiologic Data”.